Want to see CBIO full AI Analyst Report?
CBIO Stock Chart & Stats
$17.76
$0.94(5.77%)
At close: 4:00 PM EDT
$17.76
$0.94(5.77%)
Day’s Range― - ―
52-Week Range$8.72 - $27.41
Previous CloseN/A
Volume130.39K
Average Volume (3M)470.92K
Market Cap
$489.19M
Enterprise Value$383.42M
Total Cash (Recent Filing)$171.59M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 05, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend Yield55.3%
Share Statistics
EPS (TTM)-6.72
Shares Outstanding37,143,940
10 Day Avg. Volume356,061
30 Day Avg. Volume470,916
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.61
Price to Sales (P/S)11.39
P/FCF Ratio-0.86
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue32.27
Enterprise Value/Gross Profit32.27
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$30.80Price Target Upside73.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.77
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe very low debt burden reduces near-term balance-sheet pressure and leaves the company less exposed to interest costs or debt refinancing. This conservative capital structure can preserve strategic flexibility while Crescent funds clinical development, although it does not eliminate its cash needs.
Clinical Pipeline ProgressProgress across ASCEND and APOLLO shows the company is advancing multiple oncology candidates through clinical development rather than relying on a single preclinical asset. Broader clinical validation could create more durable opportunities for partnering, milestone generation, and eventual commercialization.
Pipeline Breadth And PartnershipsDevelopment across several tumor types, ADC combinations, and a China-based partner broadens the potential application of Crescent's platform. This can generate additional clinical evidence and diversify future product opportunities, while partner-led studies may extend development capacity across markets.
Bears Say
Severe Cash BurnSubstantial and worsening cash burn means Crescent must continue funding operations while its pipeline remains in development. Unless spending declines or revenue scales meaningfully, ongoing cash consumption can create recurring financing needs and reduce the resources available for clinical expansion.
Large Losses And Limited RevenueThe company has not yet achieved meaningful operating scale: modest revenue is outweighed by very large EBIT and net losses. Persistent unprofitability limits internally generated funding, increases dependence on capital access, and makes the value of future clinical programs critical to long-term financial improvement.
Equity Base ErosionDeclining equity alongside sharply negative returns indicates that the current capital base is being consumed without producing earnings. Continued erosion can weaken financial resilience over time and may constrain Crescent's ability to support its pipeline without raising additional capital or improving operating results.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $8.72 and its highest was $27.41 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $489.19M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Jul 30, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.736 by -$0.004.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $24 which represents an annual dividend yield of 55.3%. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate is -0.67.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 37,143,940 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.736. Following the earnings report the stock price went up 1.693%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.80 (73.42% Upside)
$30.80 (73.42% Upside)
Blogger Sentiment
Bullish
CBIO Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 83.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.11%
12-Months-Change
Fundamentals
Return on Equity
-97.77%
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Crescent Biopharma
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$30.80
▲(73.42% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―
Ownership Overview
11.26% Insiders
5.25% Mutual Funds
48.04% Other Institutional Investors
27.03% Public Companies and
Individual Investors